Clay Siegall Plans To Continue To Develop New Drugs To Treat Cancer

While Clay Siegall is a brilliant research scientist with a Ph.D. in Genetics who works in the biotechnology field, his WordPress blog shows that he is also interested in other areas of science. Clay Siegall posted interesting films that unearthed new information about nuclear testing done during the cold-war era and he has posted an article from NPR that urges rapid action against global warming to protect coral reefs worldwide as well.

Currently Siegall is the CEO of Seattle Genetics, a biotechnology company that he co-founded in 1997. In 1995, Siegall received the Pierce Award for his work with targeted toxins, therefore, he must be proud of his company’s first commercial product, Adcetris, which is an antibody-drug conjugates (ADC) that that delivers toxins to cancer cells, ignoring healthy cells. From his time at the National Cancer Institute to his positions as a scientist and researcher at Bristol-Myers Squibb Pharmaceutical Research Institute, Seigall’s career before Seattle Genetics was devoted to finding safer, less toxic treatment options for cancer patients.

In December 2016, Siegall talked with EP Advantage about having Adcetris used earlier in treatment regimens, instead of as a last resort. With more patients eligible for Adcetris, Seattle Genetics could expand their already healthy drug pipeline and go from being the 30th-ranked cancer drug firm to the 21st by 2022. Seigall has higher ambitions, “We think we can be the next big important biotech company,” which he plans to do by continuing to develop new cancer treatment drugs, not by sitting back and waiting for a buyout.